1Bruno S, Puerto VL, Mickiewicz E, et al. Phase Ⅱ trial of weekly i.v. Vinorelbine as a single agent in first-line advanced breast cancer chemotherapy[J]. Am J Clin Oncol, 1995, 18(5):390.
2Fumoleau P, Delado FM, Pastorino G, et al. Phase Ⅱ trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy[J]. J Clin Oncol, 1993, 11(7):1245.
4Kosmas C, Agclaki S, Giannakakis T, et al. Phase I study of vinomlbinc and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer [J]. Oncology, 2002, 62 (2): 103 - 109.
5Terenziani M, Demicheli R, Bonadonna G, et al. Vinorelbine: an active noncross - resistant drug in advanced breast cancer result from a phase Ⅱ study [ J ]. Breast Cancer Res, 1996, 39 (3): 285-291.
6Shamseddine AL, Taher A, Dabaja B. et al. Combination cisplatin - vinorelbine for relapsed and chemotherapy, pretreated metastatic breast cancer [J]. Am J Clin Oncol, 1999, 22 (3): 298-302.
7Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer[ J ]. Drugs, 2000, 59:621 - 651.
8Hino H, Kobayashi K, Hayashihara K, et al. In vitro combination effect of docetaxel (RP56976) with vinca alkaloids on cancer cell- lines[ J]. Proc Am Assoc Cancer Res, 1995, 36:299.
9Bonneterre J, Campone M, Koralewski P, et al. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase Ⅰ study[ J]. Cancer Chemotherapy and Pharmacology, 2007, 60 (3) :365 - 373.
10Savio G, Laudani A, Leonardi V, et al. Treatment of metastatic breast cancer with vinorelbine and docetaxel[ J]. Am J Clin Oncol, 2006,29(3) :276 -280.
